Vivos Therapeutics (VVOS) Other Working Capital Changes (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Other Working Capital Changes for 7 consecutive years, with $61000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Working Capital Changes fell 55.8% year-over-year to $61000.0 in Q2 2026; TTM through Jun 2026 was $380000.0, a 190.08% increase from a year earlier, with the FY2025 full-year figure at $55000.0, down 67.07% from the prior year.
• Other Working Capital Changes was $61000.0 for Q2 2026 at Vivos Therapeutics, down from $166000.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $504000.0 in Q1 2024 and troughed at -$784000.0 in Q2 2024.
• A 5-year average of -$100944.4 and a median of -$84000.0 in 2025 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes plunged 2370.37% in 2022 and jumped 271.24% in 2024, its largest moves.
• Over 5 years, Other Working Capital Changes stood at -$667000.0 in 2022, then surged by 77.06% to -$153000.0 in 2023, then jumped by 271.24% to $262000.0 in 2024, then grew by 8.02% to $283000.0 in 2025, then tumbled by 78.45% to $61000.0 in 2026.
• The last three Other Working Capital Changes figures came in at $61000.0 (Q2 2026), $166000.0 (Q1 2026), and $283000.0 (Q4 2025), per Business Quant data.